HALO


Halozyme Collaborates with ViiV Healthcare to Develop Ultra-Long-Acting HIV Meds

Biopharmaceutical company Halozyme Therapeutics (HALO) has entered into a global collaboration and licensing agreement with ViiV Healthcare to further the development of ultra-long-acting …

Company Update (NASDAQ:HALO): Halozyme Therapeutics, Inc. Provides Clinical Program Updates and 2017 Financial Guidance

Halozyme Therapeutics, Inc. (NASDAQ:HALO) provided program updates and its annual financial guidance at the 35th annual JP Morgan Healthcare Conference.

Stock Update (NASDAQ:HALO): Here’s Why Halozyme Therapeutics, Inc. Shares Are Rising 19%

Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported topline results from the combined analysis of Stages 1 and 2 and Stage 2 alone of its HALO …

Stock Update (NASDAQ:HALO): Here’s Why Halozyme Therapeutics, Inc. Shares Are Tumbling 10% Today

Halozyme Therapeutics, Inc. (NASDAQ:HALO) investors are heading for the hills after the drug maker announced that AbbVie has discontinued a development program using the …

Company Update (NASDAQ:HALO): Halozyme Therapeutics, Inc. Announces Broad Clinical Collaboration Agreement To Evaluate PEGPH20 And Tecentriq In Up To Eight Tumor Types

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced an agreement to collaborate on clinical studies evaluating up to eight different tumor types beginning in 2017.

Stock Update (NASDAQ:HALO): Halozyme Therapeutics, Inc. Reports 3Q:16 Financial Results

Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported financial results and recent highlights for the third quarter ended September 30.

Company Update (NASDAQ:HALO): Halozyme Therapeutics, Inc.’s PEGPH20 Selected For Inclusion In Groundbreaking Clinical Trial Initiative

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced that its investigational drug, PEGPH20, and a companion diagnostic assay for assessment of hyaluronan (HA) under development by Ventana …

Stock Update (NASDAQ:HALO): Halozyme Therapeutics, Inc. Appoints Mark J. Gergen As Chief Operating Officer

Halozyme Therapeutics, Inc. (NASDAQ:HALO), an oncology biotech developing novel oncology and drug-delivery therapies, today named biotech veteran Mark J.

Company Update (NASDAQ:HALO): Halozyme Therapeutics, Inc. Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced that it has resumed the enrollment and dosing of patients in its ongoing Phase 1b trial evaluating its …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts